Abstract
Purpose The aim of this study was to investigate the potential benefits of prolonged treatment with neoadjuvant letrozole. Patients and Methods About 182 consecutive patients have been treated in Edinburgh with neoadjuvant letrozole for 3 months or longer and 63 patients have continued on letrozole beyond 3 months. Outcomes are reported. Results Of the 63 patients who continued on letrozole, 38 patients took letrozole for more than 1 year and 23 took letrozole for more than 24 months. The median reduction in clinical volume in the first 3 months in these 63 patients was 52%. Similar reductions in median clinical volume were seen between three to 6 months (50%), 6–12 months and 12–24 months (medians 37 and 33%, respectively). At 3 months 69.8% of the 182 patients had a partial or complete response. The response rate increased to 83.5% with prolonged letrozole treatment. Continuing letrozole beyond 3 months increased the number of women who initially required mastectomy or had locally advanced breast cancer who were subsequently suitable for breast conserving surgery from 60% (81/134) at 3 months to 72% (96/134). Thirty-three women remain on letrozole alone (man age at diagnosis 83 years) and at 3 years the median time to treatment failure has not been reached. Conclusion Continuing letrozole in responding patients beyond 3–4 months achieves further clinical reduction in tumour size. For elderly women with a short life expectancy letrozole alone may provide long-term disease control.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bear H (1998) Indications for neoadjuvant therapy for breast cancer. Semin Oncol 25(Suppl 3):S3–S12
Perloff M, Lesnick GJ (1982) Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 117:879–881
Schick P, Goodstein J, Moor J et al (1983) Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 22:278–282
Bonadonna G, Veronesi U, Brambilla C et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of 3 cm or more. J Natl Cancer Inst 82:1539–1545
Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ (2005) Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 16:267–272
van der Hage JA, van de Velde CJH, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19(22):4224–4237
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102
Dixon JM, Love CDB, Bellamy COC, Cameron DA, Leonard RCF, Smith H, Miller WR (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66(3):191–199
Dixon JM, Jackson J, Renshaw L, Miller WR (2003) Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 86:295–299
Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11):1527–1532
Smith I, Dowsett M, Ebbs SR (2005) On behalf of the IMPACT Trialists: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicentre, double-blind randomized trial. J Clin Oncol 23(22):4842–4844
Semiglazov VF, Semiglazov VV, Ivanov VG et al (2005) Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER + breast cancer patients (T1-4, N1-2, M0). Proc Am Soc Clin Oncol 23(16s):Abstract 530
Bear HD, Anderson S, Smith RE et al (2004) A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preop AC followed by docetaxel (T) and to preop AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 88(suppl 1):S16, Abstract 26
Dixon JM, Love CDB, Bellamy COC et al (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Br Ca Res Treat 66(3):191–199
Gazet JC, Ford HT, Coombes RC et al (1994) Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20(3):207–214
Kenny FS, Robertson JFR, Ellis IO et al (1998) Long-term follow-up of elderly patients randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 7:335–339
Fentiman IS, Christiaens MR, Paridaens R et al (2003) Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 39:306–316
Hind D, Wyld L, Beverley CB, Reed MW (2007) Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database of Systematic Reviews Issue 2
Mustacchi G, Ceccherini R, Milani S et al (2003) Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14(3):414–420
Fennessy M, Bates T, MacRae K et al (2004) on behalf of the Closed Trials Working Party of the Cancer Research UK Breast Cancer Trials Group: Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 91(6):699–704
Bates T, Fennessy M, Riley DL et al (2001) On behalf of the CRC Breast Cancer Trials Group UK: Breast Cancer in the Elderly: Surgery improves survival. The results of a Cancer Research Campaign Trial. Eur J Cancer 37(suppl 5):0–19
Willsher PC, Robertson JFR, Jackson L, al Hilaly M, Blamey RW (1997) Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast 6:150–154
Capasso I, Nuzzo F, Labonia V, Landi G, Rossi E, de Matteis A (2000) Surgery and tamoxifen versus tamoxifen as treatment of stage I and II breast cancer in over 70 years old women: Ten years follow-up. Ann Oncol 11(suppl 4):20
Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1 and/or erbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 19(18):3808–3816
Macaskill EJ, Dixon JM (2007) Neoadjuvant use of endocrine therapy in breast cancer. Breast 13(3):243–250
Horobin JM, Preece PE, Dewar JA et al (1991) Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78(2):213–217
Miller WR, Krause A, Evans DB et al (2005) Phenotypes for endocrine resistance can be indentified by RNA microarray of sequential biopsies and are more variable than those predicting for tumour response. Breast Cancer Res Treat 94(suppl 1):S17, Abstract 31
Dixon JM (2005) Surgical issues surrounding the use of aromatase inhibitors. J Steroid Biochem Mol Biol 95:97–103
Acknowledgements
Thanks to the Dunhill Medical Trust who provided research Fellowships to Juliette Murray and Oliver Young. This work was supported in part by an unlimited educational grant from Novartis Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dixon, J.M., Renshaw, L., Macaskill, E.J. et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 113, 145–151 (2009). https://doi.org/10.1007/s10549-008-9915-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-9915-6